Prima Biomed has two programs in place. The lead program, CVac™ has completed phase II clinical trials and focuses on the development of an ex-vivo immunotherapy for ovarian cancer. Prima is currently undertaking a Phase IIb clinical study in the US and Australia, and has commenced a global phase II/III program in 2012, with a goal to commercialize CVac™ in multiple world markets.
The second program is a collaborative venture with the University of New South Wales and University of Queensland to create a technology enabling oral administration of vaccines that are currently injected. The lead target for this program is to create an oral vaccine against Human Papilloma Virus (HPV), a virus associated with development of cervical cancer.